This page contains exclusive content for the member of the following sections: TTS, ISODP
Presenter: Josette M., Eris, Camperdown, Australia
Authors: Wai Lim, Hung Do Nguyen, Germaine Wong, Kirsten Howard, Frans Claas, Jonathan Craig, Samantha Fidler, Lloyd D'Orsogna, Jeremy Chapman, Ashley Irish, Paolo Ferrari, Frank Christiansen
Modelling the benefits and costs of integrating an acceptable HLA mismatch allocation model for highly-sensitised patients
Wai Lim1, Hung Do Nguyen1, Germaine Wong2,3, Kirsten Howard2, Frans Claas4, Jonathan Craig2,3, Samantha Fidler5, Lloyd D'Orsogna5, Jeremy Chapman3, Ashley Irish6, Paolo Ferrari7, Frank Christiansen5
1Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Australia, 2Sydney School of Public Health, The University of Sydney, Sydney, Australia, 3Centre for Kidney Research, The Childrenâ€™s Hospital at Westmead & Centre for Transplant and Renal Research, Westmead Hospital, Sydney, Australia, 4Eurotransplant Reference Laboratory, Department Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, Netherlands, 5Department of Clinical Immunology, Royal Perth Hospital, Perth, Australia, 6Department of Renal Medicine, Royal Perth Hospital, Sydney, Australia, 7Department of Renal Medicine, Fremantle Hospital, Perth, Australia
Background: The Eurotransplant acceptable mismatch program has improved transplantation access for highly-sensitised recipients. However, the benefits and costs of implementing such a program remain unknown.
Methods: Using decision analytical modelling, we compared the average waiting time for transplantation, overall survival gains (in life-years and quality-adjusted life-years gained) and costs of integrating an acceptable mismatch allocation model compared with the current deceased-donor kidney allocation model in Australia.
Results: Acceptable mismatches were identified in 12 of 28 (43%) highly-sensitised recipients using HLAMatchmaker. Inclusion of acceptable mismatches in the current allocation model improved the transplantation access for 4 (14%) highly-sensitised recipients, with an average reduction in waiting time of 34 months (from 86 to 52 months). Compared with the current allocation model, incorporating an acceptable mismatch allocation model achieved an overall lifetime gain of 0.034 quality-adjusted life-years and savings of over $4,000 per highly-sensitised patient, with a small consequential loss of 0.005 quality-adjusted life-years and extra costs of $800 for every reallocated patient.
Conclusions: Despite modest overall health gains, application of an acceptable mismatch allocation model is an equitable approach to improve transplantation access for highly-sensitised transplant candidates without compromising the overall health benefits among the other patients on the deceased-donor waitlist in Australia.
By viewing the material on this site you understand and accept that:
The Transplantation Society
505 Boulevard René-Lévesque Ouest
Montréal, QC, H2Z 1Y7